Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

4D Molecular Therapeutics (FDMT) Receivables - Other (2019 - 2022)

4D Molecular Therapeutics (FDMT) has disclosed Receivables - Other for 3 consecutive years, with $700000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Receivables - Other changed 0.0% to $700000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $700000.0, a 0.0% change, with the full-year FY2022 number at $700000.0, changed 0.0% from a year prior.
  • Receivables - Other was $700000.0 for Q4 2022 at 4D Molecular Therapeutics, roughly flat from $700000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $700000.0 in Q4 2021 to a low of $149000.0 in Q4 2019.
  • A 3-year average of $527500.0 and a median of $630500.0 in 2021 define the central range for Receivables - Other.
  • Biggest YoY gain for Receivables - Other was 0.0% in 2022; the steepest drop was 0.0% in 2022.
  • 4D Molecular Therapeutics' Receivables - Other stood at $149000.0 in 2019, then skyrocketed by 369.8% to $700000.0 in 2021, then changed by 0.0% to $700000.0 in 2022.
  • Per Business Quant, the three most recent readings for FDMT's Receivables - Other are $700000.0 (Q4 2022), $700000.0 (Q4 2021), and $561000.0 (Q1 2021).